Overview

Efficacy and Safety of Topical Nicotinamide in Treatment of Discoid Lupus Erythematosus

Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
0
Participant gender:
All
Summary
Cutaneous lupus erythematosus (CLE) is lupus affecting the skin. In this autoimmune disease, the body's immune system attacks healthy skin. There are 3 main types: Acute cutaneous lupus, Subacute cutaneous lupus, and Chronic cutaneous lupus ("discoid lupus"). Lupus most often appears between the ages of 20 and 50 years; it affects women more than men, and it may happen more in patients with a family history of lupus or other autoimmune diseases.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Al-Azhar University
Treatments:
Niacin
Niacinamide
Nicotinic Acids
Criteria
Inclusion Criteria:

- Age: between 18 years and 65 years old

- Patients clinically and histopathologically newly diagnosed as DLE

- Patients clinically and histopathologically diagnosed with cutaneous lupus
erythematosus that has not responded to treatment with
hydroxychloroquine(200-400mg/day) plus corticosteroid at a dosage less than the
equivalent of (0.5mg/kg/day) for the preceding two months or a longer period

Exclusion Criteria:

- Age < 18 years old

- Pregnant and lactating women

- A history of treatments with multivitamins in the recent month

- Soft tissue infection

- Severe comorbidities including heart failure, respiratory failure

- Acute severe infections such as cellulitis or a history of HBV or HCV